Cabergoline

C3H5NO 109-90-0) see Alfentanil Cabergoline ethyl isocyanatoaeetate (C5H7NO3 2949-22-6) see Flumazenil ethyl isonicotinate... 

Amantidine, bromocriptine, mazindol, pergolide, cabergoline, L-dopa/carbidopa, pramipexole, ABT-431, catecholamine metabolism inhibitors (disulfiram, phenelzine, selegiline), amineptine Methylphenidate, /-amphetamine, tropanes, GBR-12909 (partial agonist that may also act as antagonist), modafinil, coca tea... 

Common side effects include nausea, vomiting, sedation (highest with apomorphine), pedal edema, orthostatic hypotension (highest with pramipexole and cabergoline), and... 

Women who become pregnant while on a dopamine agonist should discontinue treatment immediately to minimize fetal exposure. Because cabergoline has a long half-life, women who plan to become pregnant should discontinue the drug at least 1 month before planned conception. 

Cabergoline (Dostinex ) 0.5 mg/week or 0.25 mg twice/week 0.5 mg increment at 4-week intervals 1-2 mg/week 4.5 mg/week Once or twice weekly Similar but orthostatic hypotension less common ... 

Shoptaw S., Watson D.W., Reiber C. et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction. 100(Suppl. 1) 78, 2005. 

Other neuromodulatory agents include bromocriptine, cabergoline, valproic acid, octreotide, and rosiglitazone. 

Dopamine receptor agonists. Deficient dopaminergic transmission in the striatum can be compensated by ergot derivatives (bromocriptine p. 114], lisu-ride, cabergoline, and pergolide) and nonergot compounds (ropinirole, prami-pexole). These agonists stimulate dopamine receptors (D2, D3, and D sub-types), have lower clinical efficacy than levodopa, and share its main adverse effects. 

The dopamine D2 agonists bromocriptine and cabergoline (pp. 114, 188) inhibit prolactin-releasing AH cells (indications suppression of lactation, prolactin-producing tumors). Excessive, but not normal, growth hormone release can also be inhibited (indication acromegaly) (3). 

Bromocriptine (11), pergolide (12), cabergoline (13) and lisuride (14) are examples of compounds which have been developed in this way and are now used clinically. The pharmacological differences between the compounds is not very great. All are D2-dopamine receptor agonists, although... 

Pastor P Tolosa E, Cabergoline in the treatment of Parkinson s disease, Neurologia 18 202-209, 2003. 

---